GlassScriptPhysician profile
Stephen M Schultz
NPI 1033188719
$12,592.93
in general payments reported to CMS, 2019-2025
69 companies · $2,286 in 2025
The $2,286 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,200 · 2020: $460 · 2021: $771 · 2022: $2,311 · 2023: $2,172 · 2024: $2,392 · 2025: $2,286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,827 · Education: $23.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,826.95 |
| Education | $23.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,280.43 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,052.67 | 2019-2025 | Kisqali, Piqray |
| Janssen Biotech, INC. | $801.98 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Astrazeneca Pharmaceuticals LP | $735.42 | 2019-2025 | Enhertu, Lynparza, Tagrisso |
| Amgen INC. | $662.86 | 2019-2024 | Kyprolis, Blincyto, Lumakras |
| Genzyme Corporation | $629.54 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $628.58 | 2019-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $569.40 | 2019-2025 | Keytruda, Welireg, Reblozyl |
| Astellas Pharma US INC | $461.40 | 2019-2025 | Padcev, Xtandi |
| Gilead Sciences, INC. | $457.55 | 2019-2025 | Trodelvy |
| Genentech USA, INC. | $432.98 | 2019-2024 | Venclexta, Tecentriq, Rozlytrek |
| Celgene Corporation | $396.00 | 2019-2025 | Reblozyl, Pomalyst |
| Tg Therapeutics, INC. | $341.12 | 2022 | |
| Abbvie INC. | $291.54 | 2022-2025 | Venclexta |
| Exelixis INC. | $287.26 | 2019-2025 | Cabometyx |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.